A recent multinational randomized phase III trial reported that GnRH antagonist therapy, compared with a GnRH agonist, reduced adverse CV events by 54% in a total of 930 patients with advanced PC (GnRH agonist group, n = 308; GnRH antagonist group, n = 622) [128]. Here, GNRH1 is linked to pachyonychia congenita.